Boehringer Ingelheim Animal Health has announced the launch of Fencovis, a new calf scour vaccine with a prevention claim, which will be available in the UK and Ireland before the end of the year. 

A 2021 German study reported the incidence of diarrhoea to be 18.5% and the most common disease observed in almost 14,000 neonatal calves examined on 731 dairy herds1.

Fencovis is indicated for the active immunisation of pregnant heifers and cows in order to stimulate the development of antibodies against bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin and to increase the level of passive immunity of calves against neonatal diarrhoea caused by bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin.

Boehringer says that in calves fed with colostrum and milk from vaccinated cows, these antibodies have been demonstrated to prevent diarrhoea caused by rotavirus and E. coli F5 (K99) adhesin and reduce the incidence and severity of diarrhoea caused by coronavirus.

Viral shedding in calves infected by rotavirus and coronavirus was also reduced by Fencovis.

Findlay MacBean, Business Head Livestock at Boehringer Ingelheim UK & Ireland, said: “We are delighted to announce the launch of Fencovis, the first vaccine that is licensed to prevent calf scour caused by Rotavirus and E. coli F5 (K99), and also reduce the incidence and severity of scour associated with coronavirus infection. ”

Fencovis is a suspension for injection which uses a non-oil adjuvant. It comes in a variety of presentations including a single dose pack.


  1. Dachrodt L, et al. J Dairy Sci. 2021;104(8):9037–9051

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.